Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 658,384
  • Shares Outstanding, K 242,053
  • Annual Sales, $ 2,220 K
  • Annual Income, $ -54,810 K
  • 60-Month Beta 1.98
  • Price/Sales 271.37
  • Price/Cash Flow N/A
  • Price/Book 3.97
Trade VBIV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +31.40%
on 11/10/20
3.02 -9.87%
on 11/18/20
+0.17 (+6.67%)
since 10/23/20
3-Month
2.07 +31.40%
on 11/10/20
5.20 -47.69%
on 08/27/20
-0.56 (-16.95%)
since 08/25/20
52-Week
0.69 +297.08%
on 11/26/19
6.93 -60.75%
on 07/20/20
+2.04 (+297.89%)
since 11/25/19

Most Recent Stories

More News
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Marketing...

VBIV : 2.72 (+9.24%)
VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive

VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.

AZN : 52.60 (-1.81%)
PFE : 36.53 (-0.19%)
GSK : 37.23 (+0.38%)
VBIV : 2.72 (+9.24%)
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM

--- 2 partial responses observed in VBI-1901 + GM-CSF study arm, with tumor reduction of more than 50%, and 7 stable disease observations across both vaccinated groups

VBIV : 2.72 (+9.24%)
AGEN : 3.51 (-3.84%)
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical...

VBIV : 2.72 (+9.24%)
VBI Vaccines Presents Phase 3 Sci-B-Vac(R) Data at The Liver Meeting(R) 2020

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of its...

VBIV : 2.72 (+9.24%)
Implied Volatility Surging for VBI Vaccines (VBIV) Stock Options

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

VBIV : 2.72 (+9.24%)
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract highlighting...

VBIV : 2.72 (+9.24%)
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the...

VBIV : 2.72 (+9.24%)
Global Chronic Hepatitis B Virus Market Report 2020: Insight, Epidemiology and Market Forecast, 2017-2030 Featuring VBI, Gilead Sciences, Roche, Janssen/Arrowhead, Regeneron, GSK/Ionis

, /PRNewswire/ -- The drug pipelines has been added to offering.

ASMB : 5.70 (+3.26%)
GILD : 59.50 (-1.24%)
GSK : 37.23 (+0.38%)
IONS : 50.24 (+0.40%)
REGN : 508.31 (+0.44%)
VBIV : 2.72 (+9.24%)
VBI Vaccines Presents Phase 3 Sci-B-Vac(R) Data at ID Week 2020(TM)

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two...

VBIV : 2.72 (+9.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

2nd Resistance Point 2.97
1st Resistance Point 2.85
Last Price 2.72
1st Support Level 2.52
2nd Support Level 2.31

See More

52-Week High 6.93
Fibonacci 61.8% 4.54
Fibonacci 50% 3.81
Fibonacci 38.2% 3.07
Last Price 2.72
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar